|Aastrom Biosciences, Inc.|
24 Frank Lloyd Wright Drive
United States - Map
Aastrom Biosciences, Inc., a clinical-stage biotechnology company, focuses on the development of cell therapies for use in the treatment of severe chronic ischemic cardiovascular diseases. The company is developing a manufacturing technology platform, the Aastrom Replicell System, which enables the expansion of a various cell types, including the production of multicellular therapies expanded from an adult patients own bone marrow that can be delivered directly to damaged tissues. Its lead product candidate include ixmyelocel-T, to treat patients with severe chronic ischemic cardiovascular diseases, such as advanced heart failure due to dilated cardiomyopathy, the third leading cause of heart failure, and critical limb ischemia. The company was founded in 1989 and is headquartered in Ann Arbor, Michigan.
|Mr. Dominick C. Colangelo Esq.,
Chief Exec. Officer, Pres, Treasurer and Director
|Mr. Daniel R. Orlando ,
Chief Operating Officer
|Dr. Sharon M. Watling PharmD,
|Mr. Gerard J. Michel MS, MBA,
Chief Financial Officer, Principal Accounting Officer and VP of Corp. Devel.
|Dr. Ross Tubo Ph.D.,
Chief Scientific Officer
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|